Table 2:
Multivariable analyses for disease-free and overall survival
| Disease-free survival | Overall survival | |||
|---|---|---|---|---|
|
|
|
|||
| Hazard ratio (95% CI) | p value* | Hazard ratio (95% CI) | p value* | |
| Treatment group | ||||
| Chemoradiotherapy | 1 (ref) | .. | 1 (ref) | .. |
| Chemoradiotherapy plus trastuzumab | 1·10 (0·78–1·55) | 0·59 | 1·14 (0·78–1·66) | 0·51 |
| Age, years | ||||
| <65 | 1 (ref) | .. | 1 (ref) | .. |
| ≥65 | 1·98 (1·40–2·80) | 0·0001 | 2·24 (1·53–3·28) | <0·0001 |
| T stage | ||||
| T1–T2 | 1 (ref) | .. | 1 (ref) | .. |
| T3 | 1·88 (1·19–2·96) | 0·0069 | 2·23 (1·30–3·83) | 0·0035 |
| Presence of adenopathy | ||||
| No | 1 (ref) | .. | 1 (ref) | .. |
| Yes—coeliac adenopathy absent | 1·08 (0·75–1·57) | 0·67 | 0·99 (0·66–1·49) | 0·97 |
| Yes—coeliac adenopathy present ≤2 cm | 1·16 (0·66–2·02) | 0·61 | 0·77 (0·40–1·46) | 0·42 |
*
χ2 using the Cox proportional hazards model for disease-free and overall survival.